Finance

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

Author of the article:

Business Wire

Published Jul 20, 2023  •  1 minute read

media

EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2023, on Thursday, August 3, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (888) 645-4404 / (862) 298-0702 (Toll-free U.S. & Canada). The audio webcast can also be accessed under “News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

Financial Post

THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY

Subscribe now to read the latest news in your city and across Canada.

  • Exclusive articles by Kevin Carmichael, Victoria Wells, Jake Edmiston, Gabriel Friedman and others.
  • Daily content from Financial Times, the world’s leading global business publication.
  • Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
  • National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
  • Daily puzzles, including the New York Times Crossword.

SUBSCRIBE TO UNLOCK MORE ARTICLES

Subscribe now to read the latest news in your city and across Canada.

  • Exclusive articles by Kevin Carmichael, Victoria Wells, Jake Edmiston, Gabriel Friedman and others.
  • Daily content from Financial Times, the world’s leading global business publication.
  • Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
  • National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
  • Daily puzzles, including the New York Times Crossword.

REGISTER TO UNLOCK MORE ARTICLES

Create an account or sign in to continue with your reading experience.

  • Access articles from across Canada with one account.
  • Share your thoughts and join the conversation in the comments.
  • Enjoy additional articles per month.
  • Get email updates from your favourite authors.

About Aurinia

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230720800635/en/

logo

Contacts

Investors/Media:
ir@auriniapharma.com

Read More

Avatar

Admin

About Author

Leave a comment

Your email address will not be published. Required fields are marked *

You may also like

Harbourfront Wealth Appoints Head of Corporate Development to Meet Firm Growth Demands
Finance

Harbourfront Wealth Appoints Head of Corporate Development to Meet Firm Growth Demands

VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) — Harbourfront Wealth Management Inc. (“Harbourfront” or the “Company”), a national leading
Eat & Beyond’s Portfolio Company, Purpose ESG, Announces Strategic Partnership with ClimateDoor
Finance

Eat & Beyond’s Portfolio Company, Purpose ESG, Announces Strategic Partnership with ClimateDoor

Expands Purpose ESG’s strategic partnership into CO2 abatement advisory and government funding services Areas of collaborations include deal sourcing, secure